News

Genprex Advances Cancer Treatment with New Patent Approval

Genprex Advances Cancer Treatment with New Patent Approval

Genprex Secures New Patent for Innovative Cancer Therapy

Genprex, Inc. (NASDAQ: GNPX), a pioneering clinical-stage gene therapy enterprise, has recently announced a significant milestone. The European Patent Office has expressed its intent to grant a patent focused on the use of Reqorsa® Gene Therapy along with PD-1 antibodies, specifically targeting the treatment of cancer.

Strengthening Intellectual Property Portfolio

This announcement highlights Genprex's commitment to enhancing its patent estate, which already encompasses multiple patents recognizing the synergy between REQORSA and immune checkpoint inhibitors. Senior Vice President of Intellectual Property and Licensing, Thomas Gallagher, shared, "We are pleased to continue bolstering our patent estate, which includes several patents for the use of REQORSA in combination with both PD-1 and PD-L1 antibodies across many markets. This new patent will further augment our intellectual property portfolio and enhance the protection surrounding REQORSA, safeguarding its application in targeted combination therapies."

Expanding to Global Markets

The forthcoming patent not only encompasses previously issued patents for REQORSA in conjunction with PD-1 antibodies but also extends its reach beyond territories like the U.S., Japan, Mexico, Russia, and Australia among others. This global focus allows Genprex to strategically position REQORSA within diverse international markets, offering patients potential new treatment avenues.

Clinical Potential of Reqorsa® Gene Therapy

REQORSA is strategically developed to work alongside established and effective cancer medications with the aim of treating lung cancer. Early studies have demonstrated REQORSA's compatibility with targeted therapies and immunotherapies, suggesting it could enhance current treatment protocols for patients fighting lung cancer and possibly extend to other types of cancer as well. The company believes that REQORSA's unique properties may provide an improved treatment option compared to existing therapies.

Lung Cancer Statistics and Future Projections

Lung cancer remains a critical public health issue in Europe, with Eurostat data showing nearly 250,000 fatalities due to lung cancer in 2021, accounting for around 20% of total cancer deaths. Moreover, lung cancer constituted approximately 11.9% of new cancer diagnoses in the EU-27, and projections estimate a 4.62 million new cases and 3.55 million deaths due to lung cancer globally by 2050 if current trends continue. This underscores the importance and urgency of developing more effective treatment options, such as those offered by Genprex.

About Genprex, Inc.

Genprex, Inc. is a trailblazer in clinical-stage gene therapies aimed at changing the lives of patients facing cancer and diabetes. The company specializes in delivering groundbreaking therapies through its innovative technologies that leverage disease-fighting genes. Through collaborations with premier institutions, Genprex is working towards advancing its pipeline of therapies to offer transformative treatment possibilities. Their approach employs a systemic, non-viral delivery system called Oncoprex®, which facilitates the delivery of gene-expressing plasmids using lipid-based nanoparticles. This process allows for a targeted attack on tumor cells, potentially revitalizing the body's ability to combat cancer.

The lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is currently under evaluation in two clinical trials focusing on treating non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). With designation as Fast Track by the FDA for both lung cancer programs and Orphan Drug Designation for SCLC, Genprex evinces a robust commitment to meeting the challenges presented by these debilitating conditions.

Investors and stakeholders are encouraged to stay updated on Genprex's developments by visiting the company's official website and subscribing to email alerts. Engagement through social media platforms is also available for continuous updates and industry news.

Frequently Asked Questions

What is the significance of the new patent granted to Genprex?

The new patent protects the use of Reqorsa® Gene Therapy in combination with PD-1 antibodies, enhancing Genprex's intellectual property portfolio and strategic position in cancer treatment.

How does Reqorsa® function in cancer therapy?

Reqorsa® is designed to work with existing cancer treatments, aiming to enhance their effectiveness through a unique gene therapy approach that targets tumor cells directly.

What types of cancer is Reqorsa® targeted towards?

Initially, Reqorsa® is being developed for lung cancer treatments, with potential applications for other types of cancer as research continues.

How does Genprex's approach differ from traditional cancer therapies?

Genprex's therapies utilize gene delivery systems to target cancer cells more effectively, potentially revitalizing the body’s own ability to fight illness compared to traditional methods.

Where can investors find more information about Genprex?

Investors can find more information by visiting Genprex's official website, where they can also sign up for press releases and updates.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 374

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 328

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 44

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 309

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 233

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 415

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 136

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 7

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 119

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating 50 Years: Mobil 1™ and Autodromo Partner Up

Updated Category News Views 237

Mobil 1™ Celebrates Milestone with Unique Autodromo Collaboration In a remarkable celebration of its 50-year anniversary, Mobil 1™, a pioneer in synthetic motor oil, has teamed up with Autodromo, renowned for its driving-inspired watches. This collaboration introduces the Mobil 1 Edition Monoposto, a limited-edition timepiece, showcasing their shared commitment to...

Continue Reading
diaMentis Introduces Innovative Breakthrough in Mental Health Diagnosis

Updated Category News Views 256

Advancements in Mental Health Diagnosis diaMentis, known for its forward-thinking diagnostic support technology, is making waves in the mental health sector by revealing groundbreaking results that enhance the diagnosis of mental illnesses. These findings not only signify a major breakthrough, but also represent a turning point for the company, enhancing its reputation in...

Continue Reading
CleanSpark's Impressive Growth: Achieving 30 EH/s in Hashrate

Updated Category News Views 77

CleanSpark's Breakthrough in Hashrate Efficiency CleanSpark Inc. (NASDAQ: CLSK), renowned as America's leading bitcoin miner, recently reached an operational hashrate of 30 EH/s (exahashes per second). This significant milestone reflects the company's remarkable growth and innovation in the competitive bitcoin mining industry. Transformative Growth through Strategic...

Continue Reading
Baidu's Bold Move: Aiming to Compete in Global Robotaxi Market

Updated Category News Views 108

Baidu's Ambitious Expansion Plans in Robotaxi Services Baidu Inc. is reportedly considering an exciting venture to extend its renowned robotaxi service, Apollo Go, into international markets. This bold decision follows a significant transition within the company as its CFO, Rong Luo, assumes a new role. Such developments signal Baidu's commitment to unlocking new avenues...

Continue Reading
Airship AI Secures Major Federal Contracts Amid Growing Demand

Updated Category News Views 198

Airship AI Achieves Significant Federal Contracts REDMOND, Wash. — Airship AI Holdings, Inc. (NASDAQ: AISP) is celebrating a remarkable accomplishment in the realm of public safety and security. The company has recently secured 16 individual contracts from various federal law enforcement agencies, highlighting the ongoing relevance and necessity of AI technologies in...

Continue Reading